Unveiling 10 Analyst Insights On Gilead Sciences
Portfolio Pulse from Benzinga Insights
Gilead Sciences (NASDAQ:GILD) has been analyzed by 10 analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target has increased to $77.5. Analysts have adjusted their ratings and price targets, reflecting their views on Gilead's market position and financial performance. Gilead's market cap, revenue growth, net margin, ROE, ROA, and debt management are highlighted as key financial metrics.
September 04, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences has received mixed analyst ratings, with an average 12-month price target of $77.5, up from $75.33. Analysts have adjusted their ratings and price targets, indicating varied expectations for Gilead's performance. The company's strong financial metrics, including a 23.21% net margin and 9.01% ROE, highlight its robust market position.
The increase in the average price target and the positive financial metrics such as net margin and ROE suggest a positive short-term outlook for Gilead Sciences. The mixed analyst ratings indicate some uncertainty, but the overall financial health and market position of the company are strong.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100